- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BeiGene, AbbVie patent spat to get trial from USPTO appeals board | 3 | Seeking Alpha | ||
| Mi | Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors | 7 | CNBC | ||
| Di | Ludwigshafen: Abbvie investiert | 6 | Deutsches Ärzteblatt | ||
| Di | Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher | 7 | MarketBeat | ||
| Mo | Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition | 13 | Investing.com | ||
| Mo | AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales | 10 | Investor's Business Daily | ||
| Mo | Peeling Back The Layers: Exploring AbbVie Through Analyst Insights | 8 | Benzinga.com | ||
| Mo | AbbVie investiert rund 150 Millionen Euro in die Zukunft der Spitzenforschung am Standort Ludwigshafen | 309 | news aktuell | Ludwigshafen (ots) - - Modernste Rahmenbedingungen für Forscher*innen im Kampf gegen u.a. Alzheimer und Krebs - Investition unterstreicht Bedeutung des rheinland-pfälzischen Standorts für AbbVie im... ► Artikel lesen | |
| Mo | These Pharmaceutical Firms are on Sale: AbbVie, Pfizer, and Gilead | 39 | Baystreet.ca | ||
| Mo | AbbVie shares positive results for Rinvoq in head-to-head atopic dermatitis study | 7 | PMLiVE | ||
| Mo | Street View: AbbVie's Humira to be key debate through 2025 | 9 | Reuters | ||
| Fr | Why AbbVie Stock Stumbled Today Despite the Earnings Beat | 53 | The Motley Fool | ||
| Fr | AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump | 38 | Investopedia | ||
| Fr | AbbVie stock slides 6% amid concerns about falling Humira sales | 35 | Seeking Alpha | ||
| Fr | AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod | 17 | FiercePharma | ||
| Fr | AbbVie tries to reassure investors on Humira biosimilar threat | 17 | BioPharma Dive | ||
| Fr | Kursverluste für das Wertpapier von AbbVie (149,5202 €) | 372 | ARIVA.de | Im US-amerikanischen Wertpapierhandel notiert das Wertpapier von AbbVie gegenwärtig ein wenig leichter. Zuletzt zahlten Investoren für das Wertpapier 159,87 US-Dollar. An der US-amerikanischen Börse... ► Artikel lesen | |
| Fr | AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial-again | 14 | FiercePharma | ||
| Fr | Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and Colgate | 48 | CNBC | ||
| Fr | AbbVie Q1 report beats Street despite plunging Humira sales | 18 | Seeking Alpha |
Seite:
1 2 3 4 5 Weiter >>
504 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IM CANNABIS CORP | 1,160 | 0,00 % | Pre-market Movers: IMCC, CVRX, TGTX, ROOT, PLTN. | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,365 | 0,00 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| LYRA THERAPEUTICS | 5,270 | +2,13 % | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| HARROW | 10,410 | 0,00 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| OMNIAB | 4,545 | +2,36 % | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
| NEUROGENE | 33,730 | 0,00 % | Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,860 | 0,00 % | Pre-market Movers: Zhongchao, Redwoods Acquisition Corp., Tritium DCFC, Nexalin Technology, Sunshine Biopharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.05 A.M. ET).In the Green Zhongchao Inc. (ZCMD) is up over 96% at $2.83.
Redwoods... ► Artikel lesen | |
| SOLID BIOSCIENCES | 9,540 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,590 | +3,25 % | Iterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 3,260 | +6,54 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 2,220 | 0,00 % | Pre-market Movers: Barfresh Food, Processa Pharmaceuticals, reAlpha Tech, Biophytis, Meta Platforms | ARMONK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Barfresh Food Group, Inc. (BRFH) is up over 96% at... ► Artikel lesen | |
| ELEVAI LABS | 0,678 | 0,00 % | Elevai Labs Inc.: Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments | ||
| INTERCURE | 2,960 | 0,00 % | InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million | NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 1,370 | 0,00 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement | Boston (April 29, 2024) - Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,... ► Artikel lesen | |
| BIONANO GENOMICS | 0,970 | +9,83 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen |
ABBVIE INC CDR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +11,92 % bei einem Aktienkurs von 16,900 Euro. Die Dividendendrendite beträgt aktuell +0,91 % (berechnet anhand der Ausschüttung von 0,15 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
